Brentuximab - Research Grade Biosimilar

• Background:

  Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

• NCBI Gene ID:

  943

• Swiss Prot:

  P28908

• Accession Number:

  P28908

• Immunogen:

  Humanized / TNFRSF8 (CD30, D1S166E, Ki-1) [Homo sapiens]

• Clonality:

  Recombinant Monoclonal

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies, Biosimilars

• Source:

  CHO cells

• Field of Research:

  Other

• Purification:

  >95%

• Concentration:

  Batch dependent

• Purity:

  >95%

• Buffer:

  PBS buffer pH 7.5

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks) . Store at -20 °C 12 months. Store at -80°C long term.

• Fragment:

  Human IgG1

• Symbol:

  TNFRSF8

• NCBI Official Name:

  TNF receptor superfamily member 8

• NCBI Organism:

  Homo sapiens

• Other Product Names:

  CD30; Ki-1; D1S166E